预约演示
更新于：2026-05-13
Tandospirone Citrate
枸橼酸坦度螺酮
更新于：2026-05-13
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C27H37N5O9 |
InChIKeyDMLGUJHNIWGCKM-DPFKZJTMSA-N |
CAS号112457-95-1 |
关联
33
项与 枸橼酸坦度螺酮 相关的临床试验CTR20254368
一项开放、平衡、随机、多剂量、双交叉评估空腹状态下在中国成人健康受试者体内枸橼酸坦度螺酮缓释片(规格：30mg；1次/天)与Sediel®枸橼酸坦度螺酮片(规格10mg；3次/天)的药代动力学对比研究。
CTR20244057
枸橼酸坦度螺酮片在健康受试者中空腹与餐后条件下开放、随机、单次给药、两制剂、两序列、四周期完全重复交叉设计生物等效性试验。
ChiCTR2300075407
The mechanism of Escitalopram combined with tandospirone on sleep disorder and cognitive impairment in patients with vascular depression
100 项与 枸橼酸坦度螺酮 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸坦度螺酮 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸坦度螺酮 相关的专利（医药）
登录后查看更多信息
305
项与 枸橼酸坦度螺酮 相关的文献（医药）2026-04-01JOURNAL OF AFFECTIVE DISORDERS
Efficacy of escitalopram plus tandospirone in treating vascular depressive mood disorder: A 12-week single-center randomized controlled trial
Article
作者: Zeng, Guiying ; Wei, Xinyue ; Chen, Ronghua ; Zhang, Jiabao ; Chen, Hongbin ; Liu, Nan ; Xiao, Yingchun ; Xie, Sengpei ; Huang, Yanzhen ; Zhu, Chenxi ; Wu, Shufang
BACKGROUND:
Mood disorders are important clinical manifestations of vascular depression (VaDep). We explored the efficacy of escitalopram plus tandospirone citrate in treating VaDep and the involvement of blood neurotransmitters during the treatment.
METHODS:
This single-center, double blind, randomized controlled study randomly divided patients with VaDep into Monotherapy group (escitalopram + placebo) or Combined group (escitalopram + tandospirone citrate). The primary outcome measures were the changes in psychological assessment scales from baseline to week 12, including the Hamilton Anxiety Scale (HAMA), Hamilton Depression Rating Scale (HAMD), Patient Health Questionnaire-15 (PHQ-15), Somatic Symptom Scale (SSS).
RESULTS:
Compared with the Monotherapy group, the Combined group reported a significant decrease in the HAMD score at post-treatment week 2 (95 % CI 3.97 to 5.85, p < 0.001), in the PHQ-15 score at post-treatment weeks12 (95 % CI 0.54 to 1.37, p < 0.001), and increased in platelet 5-HT1AR at post-treatment weeks 12 (95 % CI 0.08 to 0.29, p < 0.0001). In both groups, the level of platelet 5-HT1BR was significantly lower at post-treatment week 12 than before the treatment (p < 0.001). The mediation analysis showed that tandospirone ameliorated somatization symptoms by alleviating depression, with platelet 5-HT1BR playing a regulatory role by alleviating depression (β = 0.28; 95 % CI: 0.25 to 0.31).
CONCLUSION:
Combination treatment significantly improves anxiety, depression, and somatization symptoms in patients with VaDep in which platelet 5-HT1AR and platelet 5-HT1BR are potential objective indicators. These findings may provide clinical insights for the treatment of VaDep.
2026-03-01PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Assessment of Off‐Label Psychotropic Drug Use in Children and Adolescents: A Multi‐Center Cross‐Sectional Study in China
Article
作者: Li, Liu‐Cheng ; Li, Cai‐Dong ; Lei, Wen‐Juan ; Wang, Ya‐Ya ; Wu, Jun ; Teng, Yue‐Peng ; Yue, Cui‐Li ; Meng, Min
ABSTRACT:
Purpose:
This study aimed to assess the use of psychotropic drugs in children and adolescents and their off‐label use in clinical settings across multiple hospitals in China, as well as to further analyze the influencing factors of off‐label use and evidence‐based medical evidence.
Methods:
A multi‐center retrospective cross‐sectional investigation was conducted in secondary and tertiary public hospitals. The study collected prescriptions for patients under 18 years old, which contained psychotropic drugs, including antidepressants, antianxiety drugs, antipsychotics, mood stabilizers, and psychostimulants. Evidence for the prescription was determined by the clinical practice guidelines and Thomson Grades in the Micromedex. Logistic regression analysis was used to explore the influencing factors of off‐label use of psychotropic drugs.
Results:
A total of 1261 medical records involving 34 kinds of psychotropic drugs for 813 children and adolescent patients were identified. Among them, off‐label medical records accounted for 74.2% (936 medical orders), and the three most‐used off‐label drugs include fluvoxamine, tandospirone, and sertraline. Among patients with off‐label drug use, the incidence was significantly higher in females than in males, while the incidence in adolescents (12–17 years old) was significantly higher than that in children (2–11 years old) (
p
< 0.05). The types of off‐label drug use among all the included psychotropic drugs were mainly over‐age (45.9%) and unapproved indication use (36.2%). Multiple logistic regression revealed that female (OR = 1.134, 95% CI [1.027, 1.749],
p
= 0.031) and adolescent (OR = 2.520, 95% CI [1.181, 5.374],
p
= 0.017) were related to a higher risk of off‐label use of psychotropic drugs when compared to male and children, respectively. Twenty‐one kinds (61.8%) of off‐label drug types were identified, among which 15 kinds of psychotropic drug use were not supported by evidence‐based medical evidence.
Conclusion:
Off‐label use of psychotropic drugs is highly prevalent in children and adolescents. The use of psychotropic drugs should be based on instructions and evidence‐based medical evidence to ensure their rational use in these patient populations. The drug administration should standardize the practice of pediatric prescription in the future.
2025-12-01PCN reports : psychiatry and clinical neurosciences
Psychosis induced by invocation presenting as possession state: A case of Kitousei‐Seishinbyo still emerging in modern Japan
Article
作者: Miyano, Fumiya ; Kato, Takahiro A. ; Fujii, Yutaka ; Mitsui, Nobuyuki
Abstract:
Background:
Kitousei‐Seishinbyo, or psychosis induced by invocation, was first described by Morita in 1915 as a culture‐bound syndrome characterized by possession‐like states and personality transformation triggered by prayer or spiritual practices. New psychosocial triggers (e.g., self‐improvement seminars, emerging religious groups) have been identified. However, reports of possession‐related episodes have become extremely rare. Diagnostic confusion with dissociative identity disorder or other specified dissociative disorders persists.
Case Presentation:
A woman in her 50s, with no prior psychiatric history, developed acute possession‐like symptoms after visiting a fortune‐teller. She was told her misfortune was caused by the spirit of her aborted child. Soon after, she entered trance states, spoke in altered voices (male and childlike), and exhibited personality changes, agitation, and dangerous behaviors, leading to involuntary admission. On evaluation, laboratory tests, electroencephalogram (EEG), and imaging were unremarkable. During hospitalization, she exhibited mutism, rigidity, temporary auditory hallucinations, and somatic complaints such as heaviness and dizziness, which fluctuated depending on spiritual contact. Retrospective review revealed significant psychosocial stressors, including marital discord, caregiving burden, and strained family relationships. Management involved family psychoeducation, occupational therapy, and low‐dose psychotropics (tandospirone and zolpidem). Her symptoms gradually stabilized, and she voluntarily discontinued spiritual practices. She was discharged after 62 days with improved family dynamics and sustained recovery.
Conclusion:
This case illustrates a present‐day example of Kitousei‐Seishinbyo triggered by encountering a fortune‐teller. Improvement was achieved through combined psychosocial interventions and low‐dose pharmacotherapy.
68
项与 枸橼酸坦度螺酮 相关的新闻（医药）2026-04-10
2026-03-23
2026-03-22
100 项与 枸橼酸坦度螺酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 焦虑症 | 中国 | 2003-05-21 | |
| 神经症性障碍 | 日本 | 1996-07-10 | |
| 心理生理性障碍 | 日本 | 1996-07-10 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 年龄相关性黄斑变性 | 临床3期 | - | 2009-04-01 | |
| 地图样萎缩 | 临床3期 | - | 2009-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 274 | High-dose tandospirone (60 mg/d) | 糧獵選艱願構糧夢蓋淵(膚憲觸顧願餘襯夢觸憲) = 餘鹹繭糧淵淵顧醖餘淵 襯獵醖鑰繭鏇願壓繭網 (簾壓遞齋鏇繭願襯醖選 ) 更多 | - | 2023-02-26 | ||
Low-dose tandospirone (30 mg/d) | 糧獵選艱願構糧夢蓋淵(膚憲觸顧願餘襯夢觸憲) = 範壓獵醖襯鏇衊獵艱積 襯獵醖鑰繭鏇願壓繭網 (簾壓遞齋鏇繭願襯醖選 ) 更多 | ||||||
临床4期 | 274 | 鬱壓襯選淵簾遞鏇鏇淵(壓製鑰鏇艱餘艱鬱構窪) = 廠網壓獵蓋積壓鏇選壓 簾觸餘醖繭鬱築遞衊鹹 (夢選繭遞範窪衊鹽網鏇 ) | - | 2022-08-01 | |||
鬱壓襯選淵簾遞鏇鏇淵(壓製鑰鏇艱餘艱鬱構窪) = 憲憲膚齋鏇鬱構選顧製 簾觸餘醖繭鬱築遞衊鹹 (夢選繭遞範窪衊鹽網鏇 ) | |||||||
临床3期 | 772 | (AL-8309B 1.0%) | 壓淵鹽觸齋繭壓淵鏇網(網窪構醖蓋鬱繭範顧齋) = 憲繭糧艱遞壓繭築鹽觸 壓鬱淵鏇選構繭蓋襯糧 (簾鏇網醖齋鏇遞餘醖範, 繭鏇夢簾鏇艱遞衊襯願 ~ 艱壓鬱糧願選顧蓋範夢) 更多 | - | 2014-07-03 | ||
(AL-8309B 1.75%) | 壓淵鹽觸齋繭壓淵鏇網(網窪構醖蓋鬱繭範顧齋) = 糧衊觸鏇膚廠憲網糧選 壓鬱淵鏇選構繭蓋襯糧 (簾鏇網醖齋鏇遞餘醖範, 齋憲築夢餘廠簾淵襯範 ~ 襯繭積襯簾願範遞窪觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用